Skip to main content
ASBP
NASDAQ Life Sciences

Aspire-Lakewood Board Authorizes $10M Buyback; DCSC Adds $209.5M Revenue

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Biotech Stocks · Healthcare
Sentiment info
Positive
Importance info
7
Price
$8.62
Mkt Cap
$12.09M
52W Low
$3.309
52W High
$566.76
52W Position info
161% above low
Off High info
98% below high
Rel. Volume info
0.1× avg
Market data snapshot near publication time

ASBP has more than doubled off its 52-week low of $3.309 on light trading volume (0.1× avg).

Summary

Aspire-Lakewood Holdings authorized a $10 million share repurchase program, citing strong cash flow from its newly acquired Dura Control Systems subsidiary, which posted $209.5 million in 2025 revenue.


Key Events · Financing and Capital Events · ASBP

  • $10M Share Repurchase Authorized

    Board authorized a $10 million common stock repurchase program effective September 9, 2026, with no expiration date and no minimum repurchase obligation.

  • DCSC Financial Strength Cited

    Newly acquired Dura Control Systems Corp. generated approximately $209.5 million revenue and $22.3 million Adjusted EBITDA in 2025, and $103.9 million revenue and $10.5 million Adjusted EBITDA in H1 2026.

  • Management Sees Undervaluation

    CEO Kraig Higginson stated the share price does not reflect the company's financial strength or long-term growth opportunity, with Adjusted EBITDA of approximately $15.00 per share based on 1.5 million shares outstanding.

  • Name Change Formalized

    Certificate of Amendment filed September 8, 2026, changing the corporate name to Aspire-Lakewood Holdings, Inc., effective September 8, 2026; trading symbol ASBP remains unchanged.


Analysis · ASBP · Life Sciences

The board authorized a $10 million share repurchase program effective September 9, 2026, with roughly 1.5 million shares outstanding. The buyback is backed by newly acquired Dura Control Systems Corp., which generated approximately $209.5 million in revenue and $22.3 million in Adjusted EBITDA for 2025. Management states the share price does not reflect the company's financial strength, framing the repurchase as an opportunistic capital return. The program has no expiration date and may be suspended at any time.

How filings like this one have moved

In the 30 days to Sep 10, 2026, 30.2% of the 2009 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was -0.11%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, ASBP was trading at $8.62 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $12.1M. The 52-week trading range was $3.31 to $566.76. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

ASBP - Latest Insights

ASBP
Sep 09, 2026, 8:30 AM EDT
Source: ACCESS Newswire
Importance Score:
7
Price at Filing: $8.75
Real-time Price: $8.61 info
Change: -$0.140 (-2%) info
Market Cap: $12.076M info
ASBP
Aug 19, 2026, 8:30 AM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $7.65
Real-time Price: $8.61 info
Change: +$0.960 (+13%) info
Market Cap: $12.076M info
ASBP
Aug 10, 2026, 9:45 AM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $7.98
Real-time Price: $8.61 info
Change: +$0.630 (+8%) info
Market Cap: $12.076M info
ASBP
Aug 10, 2026, 8:16 AM EDT
Source: Benzinga
Importance Score:
8
Price at Filing: $7.74
Real-time Price: $8.61 info
Change: +$0.870 (+11%) info
Market Cap: $12.076M info
ASBP
Jun 22, 2026, 4:35 PM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $6.29
Real-time Price: $8.61 info
Change: +$2.32 (+37%) info
Market Cap: $12.076M info